Real-World Effectiveness of First Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights

Overview

Journal Pragmat Obs Res

Publisher Dove Medical Press

Specialty General Medicine

Date 2024 Jun 17

PMID 38881691

Authors

Tiago Biachi de Castria

Richard D Kim

Affiliations

Soon will be listed here.

Abstract

Lenvatinib received its initial approval in 2018 for the treatment of advanced hepatocellular carcinoma. It has since emerged as the preferred first line agent, supported by non-inferiority data from the REFLECT trial. Notably, lenvatinib exhibits a more favorable toxicity profile and a higher response rate compared to sorafenib. Despite the approval of immunotherapy in 2020, specifically the combination of atezolizumab and bevacizumab following the IMbrave150 trial, tyrosine kinase inhibitors remain an indispensable class of agents in the landscape of hepatocellular carcinoma treatment. This comprehensive review delves into various facets of lenvatinib utilization in hepatocellular carcinoma, shedding light on real-world data, addressing challenges, and providing insights into strategies to overcome these obstacles.

Citing Articles

Critique on "Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights" [Letter].

Goyal M, Khubber M, Mehta V Pragmat Obs Res. 2024; 15:89-90.

PMID: 38974939 PMC: 11226856. DOI: 10.2147/POR.S483062.

References

Hirsova P, Ibrahim S, Krishnan A, Verma V, Bronk S, Werneburg N . Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes. Gastroenterology. 2016; 150(4):956-67. PMC: 4808464. DOI: 10.1053/j.gastro.2015.12.037. View

Bruix J, Chan S, Galle P, Rimassa L, Sangro B . Systemic treatment of hepatocellular carcinoma: An EASL position paper. J Hepatol. 2021; 75(4):960-974. DOI: 10.1016/j.jhep.2021.07.004. View

Ogushi K, Chuma M, Uojima H, Hidaka H, Numata K, Kobayashi S . Safety and Efﬁcacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis. Clin Exp Gastroenterol. 2020; 13:385-396. PMC: 7534867. DOI: 10.2147/CEG.S256691. View

Kobayashi K, Ogasawara S, Maruta S, Okubo T, Itokawa N, Haga Y . A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study. Clin Cancer Res. 2023; 29(23):4760-4769. DOI: 10.1158/1078-0432.CCR-23-1462. View

Solinas G, Germano G, Mantovani A, Allavena P . Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009; 86(5):1065-73. DOI: 10.1189/jlb.0609385. View

Saeki I, Yamasaki T, Yamashita S, Hanazono T, Urata Y, Furutani T . Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment. Cancers (Basel). 2020; 12(4). PMC: 7225985. DOI: 10.3390/cancers12040779. View

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

Vogel A, Martinelli E . Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021; 32(6):801-805. DOI: 10.1016/j.annonc.2021.02.014. View

Haber P, Puigvehi M, Castet F, Lourdusamy V, Montal R, Tabrizian P . Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020). Gastroenterology. 2021; 161(3):879-898. DOI: 10.1053/j.gastro.2021.06.008. View

10.

Foerster F, Hoppe-Lotichius M, Vollmar J, Marquardt J, Weinmann A, Worns M . Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre. United European Gastroenterol J. 2019; 7(6):838-849. PMC: 6620871. DOI: 10.1177/2050640619840221. View

11.

Palmer M, Gile J, Storandt M, Jin Z, Zemla T, Tran N . Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study. Cancers (Basel). 2023; 15(19). PMC: 10571707. DOI: 10.3390/cancers15194867. View

12.

Boss D, Glen H, Beijnen J, Keesen M, Morrison R, Tait B . A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 2012; 106(10):1598-604. PMC: 3349182. DOI: 10.1038/bjc.2012.154. View

13.

Gordan J, Kennedy E, Abou-Alfa G, Beg M, Brower S, Gade T . Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol. 2020; 38(36):4317-4345. DOI: 10.1200/JCO.20.02672. View

14.

Taylor M, Schmidt E, Dutcus C, Pinheiro E, Funahashi Y, Lubiniecki G . The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol. 2020; 17(6):637-648. DOI: 10.2217/fon-2020-0937. View

15.

Hong D, Kurzrock R, Wheler J, Naing A, Falchook G, Fu S . Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res. 2015; 21(21):4801-10. PMC: 4840931. DOI: 10.1158/1078-0432.CCR-14-3063. View

16.

Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K . Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019; 14(2):e0212513. PMC: 6392299. DOI: 10.1371/journal.pone.0212513. View

17.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

18.

Ikeda M, Okusaka T, Mitsunaga S, Ueno H, Tamai T, Suzuki T . Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2015; 22(6):1385-94. DOI: 10.1158/1078-0432.CCR-15-1354. View

19.

Tomonari T, Sato Y, Tanaka H, Mitsuhashi T, Hirao A, Tanaka T . Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. JGH Open. 2021; 5(11):1275-1283. PMC: 8593789. DOI: 10.1002/jgh3.12663. View

20.

Singal A, Nagar S, Hitchens A, Davis K, Iyer S . Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA. Future Oncol. 2021; 17(21):2759-2768. DOI: 10.2217/fon-2021-0242. View